Recent News

Kyowa Hakko Launches Clinically-Researched Paraprobiotic for Eye Health

April 15, 2021

The EyeMuse-branded ingredient is supported by published studies, giving formulators a new option for products for consumers with digital device-related eye fatigue, from everyday professionals to gamers. Read more »

Kyowa Hakko Announces Scientific-Breakthrough for Eye Health - EYEMUSE™ Enters the U.S. Market

April 6, 2021New York, NY

Kyowa Hakko, global leaders in the research, manufacturing and purification of high-quality health ingredients, is thrilled to introduce a new perspective on eye health. Its breakthrough clinically-researched eye health ingredient, EYEMUSE™, is entering the U.S. market, becoming the first heat-treated probiotic strain for healthy eye function, discovered by Kyowa Hakko’s parent-company Kirin Holdings Co., Ltd. Read more »

Kyowa Hakko Launches Setria® Glutathione "Breathe" Campaign

February 18, 2021

Kyowa Hakko, global leaders in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products, is introducing its new “Breathe” brand campaign featuring Setria® Glutathione, a patented glutathione ingredient that supports respiratory and immune health*. Read more »

Get the "Love Bug" – Ladybug Potions® Launches I Love My Self Supplement Featuring Setria® Glutathione

February 10, 2021

Founded by cousins Cilia Fishman and Laura Khoudari, Ladybug Potions® is entering the market with its cutting-edge dietary supplement, I Love Myself, focused on making self-care a top priority for its consumers. In doing so, the dynamic duo chose to include Kyowa Hakko’s clinically-studied Setria® Glutathione ingredient as a key part of the “potion’s” formula. Read more »

Kyowa Hakko Bio Establishes New Facility in Thailand to Supply Human Milk Oligosaccharides Worldwide

November 6, 2020PRWeb.com

KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), has announced that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand. Kyowa Hakko Bio decided on the move with expectations of a future increase in global demand for HMOs. This move further expands its global footprint to consolidate its position as a global specialty fermentation manufacturer. Read more »

Kyowa Hakko Announces “IMMUSE™ LC-Plasma: A Unique Approach to Immune Health” Live Webinar

October 6, 2020

Leading international health ingredient manufacturer Kyowa Hakko is excited to announce an interactive webinar will be held on Wednesday, October 7th at 2:00pm EDT with Natural Products Insider to discuss, and educate, on the newest approach that supports the immune system. Read more »

Triple Threat – Glaxon’s New and Improved Plasm Surge Blend Features Three of Kyowa Hakko’s Branded Ingredients

October 5, 2020

Sports nutrition dietary supplement brand Glaxon launches Plasm Surge, a non-stimulant pre-workout product with a new and improved formula and flavor system, featuring leading international health-ingredient manufacturer Kyowa Hakko’s Setria® Performance Blend, Velox® Patented Performance Blend and Kyowa Quality L-Citrulline. Read more »

The Latest Breakthrough Approach in Immunity – IMMUSE™ Enters the U.S. Market

September 28, 2020New York, NY, USA

International health ingredient manufacturer Kyowa Hakko Bio Co., Ltd. (Kyowa Hakko) and parent company Kirin Holdings Co., Ltd., (Kirin Holdings) announce the launch of its novel dietary supplement ingredient IMMUSE™, delivering a new approach for broad range immune support. Read more »

'Know Your Potential' with Knosis – Cognizin® Citicoline Featured in New Nootropic + Energy Blend

September 17, 2020

New Gamer-Focused Supplement launches with Kyowa Hakko’s brain health ingredient in science-backed, transparent formula. Dietary supplement brand Knosis enters the market with the launch of its powdered Energy + Nootropic mix, a science-backed formula designed by Knosis’ founder Erik Bywater to optimally support eSports performance and energy. Read more »

Senior Pharmaceutical Drug Development Executive, Philip Chaikin, PharmD, MD, FCP, Joins NDA Partners as Expert Consultant

June 17, 2020

NDA Partners Chairman Carl Peck, MD, announced today that Dr. Philip Chaikin, a senior pharmaceutical industry executive with extensive drug development experience in development strategy, regulatory strategy, clinical pharmacology, and clinical study design, has joined the firm as an Expert Consultant. Read more »